In July 2010, Servier and Galapagos collaborated to develop new medicines for the treatment of osteoarthritis (OA).
Galapagos is responsible for the discovery and development of new candidate drugs, and Servier has an exclusive option to license these after the completion of Phase I clinical trials by Galapagos.
Galapagos CEO Onno van de Stolpe said they achieved multiple milestones, including optimization of a molecule against a novel OA target coming from their discovery platform.